Search Result

Isoforms Recommended:	CLK

Results for "

CLK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (1) Autophagy (1) Casein Kinase (1) CDK (35) Cryptochrome (1) DYRK (15) GSK-3 (5) Haspin Kinase (2) IRAK (1) MELK (2) mTOR (2) Pim (2) RIP kinase (2) Small Interfering RNA (siRNA) (6) SRPK (1) TNF Receptor (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (30) Infection (3) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (4)
Oligonucleotides:	Pre-designed siRNA Sets (6) siRNAs (6)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-115470

CLK-IN-T3 1 Publications Verification	CDK DYRK	Cancer
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC₅₀s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity .

HY-152219

CLK1-IN-2	CDK	Infection Cancer
CLK1-IN-2 is metabolically stable *Clk1* inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC₅₀ value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza .

HY-149262

CLK1-IN-3	CDK DYRK Autophagy	Cancer
CLK1-IN-3 (compound 10ad) is a potent and selective *Clk1* inhibitor, with an IC₅₀ of 5 nM and over 300-fold selectivity for Dyrk1A. CLK1-IN-3 also shows a relatively potent inhibition against *Clk2* and *Clk4, with IC₅₀* values of 42 and 108 nM, respectively. CLK1-IN-3 potently induces autophagy in vitro. CLK1-IN-3 can be used for acute liver injury (ALI) research .

HY-400528

CLK1-IN-4	CDK	Inflammation/Immunology
CLK1-IN-4 (Compound 79) is an inhibitor for CDC like kinase 1 (CLK-1) with IC₅₀ of 1.5-2 μM .

HY-103082

CLK1-IN-1	CDK	Others
CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC₅₀ of 2 nM.

HY-113825

CLK1/2-IN-1	CDK	Cancer
CLK1/2-IN-2 is *CLK1* and *CLK2* inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-113670

CLK1/2-IN-2	CDK	Cancer
CLK1/2-IN-2 is *CLK1* and *CLK2* inhibitor with IC₅₀ values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-146335

CLK1/4-IN-1	CDK	Cancer
CLK1/4-IN-1 (compound 31) is a potent and selective *Clk1* and *Clk4* inhibitor with an IC₅₀ value of 9.7 nM and 6.6 nM, respectively. CLK1/4-IN-1 has growth inhibitory activities against T24 cancer cells with GI₅₀ of 1.1 μM. CLK1/4-IN-1 can be used for researching anticancer .

HY-113831

CLK1/2-IN-3	CDK SRPK	Cancer
LK1/2-IN-3 (compound 3) is a potent and selective *CLK1* and *CLK2* inhibitor with IC₅₀ values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .

HY-130676

CLK-IN-T3N	CDK	Cancer
CLK-IN-T3N, the negative control of CLK-IN-T3 (HY-115470), is a chemical probe for CDC-like kinase (CLK).

HY-148765

CLK8	Cryptochrome	Metabolic Disease Cancer
CLK8 is a potent and specific CLOCK inhibitor that can disrupt the interaction between CLOCK and BMAL1 and interfere with nuclear translocation of CLOCK. CLK8 can be used for the research of disorders associated with dampened circadian rhythms .

HY-RS02814

CLK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK1 Human Pre-designed siRNA Set A CLK1 Human Pre-designed siRNA Set A

HY-RS02815

Clk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk1 Mouse Pre-designed siRNA Set A Clk1 Mouse Pre-designed siRNA Set A

HY-RS02816

Clk1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk1 Rat Pre-designed siRNA Set A Clk1 Rat Pre-designed siRNA Set A

HY-RS02817

CLK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK2 Human Pre-designed siRNA Set A CLK2 Human Pre-designed siRNA Set A

HY-RS02818

CLK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK3 Human Pre-designed siRNA Set A CLK3 Human Pre-designed siRNA Set A

HY-RS02819

CLK4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK4 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK4 Human Pre-designed siRNA Set A CLK4 Human Pre-designed siRNA Set A

HY-153708

*SGC-CLK-1* CAF-170	CDK	Cancer
SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. SGC-CLK-1 can inhibit the growth of melanoma and glioblastoma cells .

HY-131978

DB18	CDK	Cancer
DB18 is a potent and selective inhibitor of CDC2-like kinases (CLKs), with IC₅₀ values in the range of 10-30 nM for CLK1, CLK2 and CLK4. DB18 has anti-tumor activity .

HY-137435

Cirtuvivint 1 Publications Verification SM08502	CDK	Cancer
Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research .

HY-144875

CTX-712	CDK	Cancer
CTX-712 is an orally effective CLK 2 inhibitor, with an IC₅₀ of 1.4 nM, showing anti-tumor activity .

HY-157995

Dyrk1A-IN-7	DYRK	Metabolic Disease Inflammation/Immunology Cancer
Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC₅₀ value of DYRK1A is 28 nM. For CLK2, K_d is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases .

HY-123600

SRI-29329	CDK	Others
SRI-29329 is a specific *CLK* inhibitor, with IC₅₀ values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively .

HY-15338

TG003 3 Publications Verification	CDK	Cancer
TG003 is a potent inhibitor of *Clk1/Sty; inhibits Clk1 and Clk4 with IC₅₀* values of 20 and 15 nM, respectively .

HY-15951

ML167 CID44968231; NCGC00188654	CDK DYRK	Cancer
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC₅₀ of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B .

HY-15338A

(E/Z)-TG003	CDK	Cancer
(E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of *Clk1/Sty; inhibits Clk1 and Clk4 with IC₅₀* values of 20 and 15 nM, respectively .

HY-125202

KuWal151	CDK DYRK	Cancer
KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines .

HY-137443

Ipivivint	CDK Wnt	Cancer
Ipivivint (compound 38) is a potent CDC-like kinase (CLK) inhibitor with EC₅₀s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibits Wnt pathway (EC₅₀=13 nM) .

HY-12828A

KH-CB20	CDK DYRK	Infection Neurological Disease
KH-CB20, an E/Z mixture, is a potent and selective inhibitor of *CLK1* and the closely related isoform *CLK4, with an IC₅₀* of 16.5 nM for *CLK1. KH-CB20 can also inhibit DYRK1A* (IC₅₀=57.8 nM) and *CLK3* (IC₅₀=488 nM) .

HY-155723

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .

HY-112296

T025 2 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .

HY-12828

KH-CB19	CDK	Infection Neurological Disease
KH-CB19 is a potent *CLK* (cdc2-like kinase) inhibitor (CLK1 IC₅₀=19.7 nM; CLK3 IC₅₀=530 nM). KH-CB19 shows antiviral activity and inhibits influenza virus replication (IC₅₀=13.6 μM) .

HY-108709

CC-671 1 Publications Verification	CDK	Cancer
CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC₅₀s of 0.005 and 0.006 μM for TTK and CLK2, respectively.

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively .

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and *CLK3* inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively .

HY-162398

LQ23	CDK	Inflammation/Immunology
LQ23 is a selective inhibitor for CDC2-like kinase 2 (CLK2) with an IC₅₀ of 1.4 nM. LQ23 exhibits anti-inflammatory activity .

HY-122631

TG693	CDK	Others
TG693 is an orally active inhibitor of *CLK1*. TG693 regulates the mutated exon 31 of the dystrophin gene in vivo. TG693 is used in Duchenne muscular dystrophy (DMD) research .

HY-146586

Haspin-IN-1	Haspin Kinase CDK DYRK	Cancer
Haspin-IN-1 (compound 2a) is a haspin inhibitor with an IC₅₀ of 119 nM. Haspin-IN-1 also inbibits *CLK1* and DYRK1A with IC₅₀s of 221 nM and 916.3 nM, respectively .

HY-146587

Haspin-IN-2	Haspin Kinase CDK DYRK	Cancer
Haspin-IN-2 (compound 4) is a potent and selective haspin inhibitor with an IC₅₀ of 50 nM. Haspin-IN-1 also inbibits *CLK1* and DYRK1A with IC₅₀s of 445 nM and 917 nM, respectively .

HY-117049

Leucettine L41	CDK DYRK	Neurological Disease
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC₅₀s = 0.04, 0.035, 0.015, and 4.5 µM, respectively) . Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ_25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ_25-35 in the same model .

HY-132175

CK2 inhibitor 2	Casein Kinase	Cancer
CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC₅₀ of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC₅₀=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .

HY-122665

HTH-01-091	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and *CLK2*. HTH-01-091 can be uesd for breast cancer research .

HY-122665A

HTH-01-091 TFA	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and *CLK2*. HTH-01-091 TFA can be uesd for breast cancer research .

HY-N12625

(R)-(+)-O-Demethylbuchenavianine	CDK DYRK GSK-3	Cancer
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively .

HY-147141

HS-276	IRAK TNF Receptor	Inflammation/Immunology
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K_i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC₅₀ values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research .

HY-131909

CJ-2360	Anaplastic lymphoma kinase (ALK)	Cancer
CJ-2360 is a potent and orally active ALK inhibitor with IC₅₀s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated .

Cat. No.	Product Name	Target	Research Area

HY-P10100

RS Repeat peptide	Peptides	Others
RS Repeat peptide is a substrate peptide for Clk1 .

HY-P5454

RS Domain derived peptide	Peptides	Others
RS Domain derived peptide is a biological active peptide. (This peptide is a substrate for Clk/Sty and is phosphorylated by Clk/Sty protein kinase (Km=102 microM).)

HY-P10042

S6K Substrate	Peptides	Others
S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	HEK293 (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70096

	COQ7 Protein, Human (HEK293, His) rHu5-demethoxyubiquinone hydroxylase, mitochondrial/COQ7, His; Ubiquinone Biosynthesis Protein COQ7 Homolog; Coenzyme Q Biosynthesis Protein 7 Homolog; Timing Protein CLK-1 Homolog; COQ7	Human	HEK293
	The COQ7 protein is a key enzyme in lipid A biosynthesis and catalyzes a key hydrolysis step involving UDP-3-O-myristoyl-N-acetylglucosamine. This activity leads to the formation of UDP-3-O-myristoylglucosamine and acetate, which is a decisive point in lipid A synthesis. COQ7 Protein, Human (HEK293, His) is the recombinant human-derived COQ7 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of COQ7 Protein, Human (HEK293, His) is 181 a.a., with molecular weight of 19-22 kDa.

HY-P701664

	CLK2 Protein, Human (GST) CLK2; Dual specificity protein kinase CLK2; CDC-like kinase 2	Human	E. coli
	The CLK2 protein is a dual-specificity kinase that phosphorylates serine- and arginine-rich (SR) proteins in the spliceosome complex. CLK2 Protein, Human (GST) is the recombinant human-derived CLK2 protein, expressed by E. coli , with N-GST labeled tag. The total length of CLK2 Protein, Human (GST) is 367 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks